A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A brand new drug might be more effective at preventing HIV than current ...

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...

HIV pre-exposure prophylaxis (PrEP) is an effective and safe intervention for individuals with behaviors that are considered high risk for acquiring HIV infection. Despite the success of this ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

About The Study: This decision analytic model showed that within the context of a high SARS-CoV-2 probability, monoclonal antibodies pre-exposure prophylaxis (mAbs PrEP) provision was cost-saving when ...

Although its availability has grown during the past decade, pre-exposure prophylaxis (PrEP) remains underused in the US. We evaluated the impact of Medicaid expansion on state-level PrEP prescribing ...

Among individuals using HIV pre-exposure prophylaxis (HIV PrEP), doxycycline post-exposure prophylaxis (doxyPEP) was associated with a substantial decline in chlamydia and syphilis incidence.

Health and Human Rights, Vol. 24, No. 1, SPECIAL SECTION: Compulsory Drug Treatment and Rehabilitation, Health, and Human Rights (JUNE 2022), pp. 105-116 (12 pages) This paper examines the extent to ...